Injection site reactions after intramuscular administration of haloperidol decanoate 100 mg/mL.
The authors report four cases of injection site reaction after intramuscular administration of haloperidol decanoate 100 mg/mL. In each case, the injection site became edematous, red, pruritic, and tender, and a palpable mass remained for up to 3 months. No systemic symptoms were reported. All four patients had previously received the 50 mg/mL haloperidol decanoate injection without incident. Two of these events followed the initial injection of haloperidol decanoate 100 mg/mL. Rechallenge with the 100 mg/mL product in one case and the 50 mg/mL product in two resulted in similar reactions. The incidence of this reaction at the authors' facility is estimated to be 7.7%. The authors speculate that the reaction is most likely to be related to the concentration of haloperidol decanoate in the injection.
Hamann
G L
GL
Department of Clinical Pharmacy, University of Tennessee, Memphis.
Egan
T M
TM
Wells
B G
BG
Grimmig
J E
JE
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000633:toxicity; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004342:Drug Hypersensitivity / Q000209:etiology / Q000473:pathology; D005260:Female; D006220:Haloperidol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000633:toxicity; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000139:chemically induced / Q000473:pathology; D007273:Injections, Intramuscular; D008297:Male; D012867:Skin / Q000473:pathology; D012871:Skin Diseases / Q000139:chemically induced* / Q000473:pathology
D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; C033563:haloperidol decanoate; D006220:Haloperidol